Table 3.

Clinical trials involving novel agents in B-NHL.

Clinical Trial	Phase	Drugs	Comments	Mechanism of action	Primary Endpoints	Key Secondary Endpoints	Estimated Enrollment
NCT05424822	I	JNJ-80948543	B-NHL and CLL	CD3 x CD20 x CD79b	DLT, AEs	Pharmacokinetics, ORR, CR, TTR, DOR	180
NCT04594642	I	TNB-486	R/R B-NHL	CD19 x CD3	DLT	ORR, PFS, DOR	116
NCR04077723	I/II	RO7227166	R/R B-NHL	41BBL + CD20 X CD3	DLT, AEs, ORR, DCR, DOR, PFS, OS, CR	Pharmacokinetics, AEs, ADA, TFR, Quality of life	498
NCT05397496	I	PIT565	R/R- B-NHL	CD19 x CD3 x CD2	DLT	Pharmacokinetics, ORR, CR, OS,PFS, EFS,	140
NCT05219513	I	RO7443904	R/R- B-NHL	CD19 x CD28 + CD20 X CD3	DLT, AEs	Pharmacokinetics	53

DLT = Drug limiting toxicities; AEs = adverse effects; ORR = overall response rate; CR = complete metabolic response; TTR = time to response; DOR = duration of response; PFS = progression-free survival; OS = overall survival; DOCR = duration of complete response; ADA = anti-drug antibodies; EFS = event-free survival; DCR = Disease control rate; TFR = time to response.